晚期膀胱癌治疗的新药物研究进展  

Research Development of New Agents for the Treatment of Advanced Bladder Cancer

作　　者：庞亮[1] 刘光明[2] 姚世杰[2] 

机构地区：[1]天津市职业病防治院天津市工人医院泌尿外科,天津300011 [2]天津市第一中心医院泌尿外科,天津300192

出　　处：《医学综述》2017年第24期4829-4834,共6页Medical Recapitulate

摘　　要：晚期膀胱癌的临床预后较差。针对晚期膀胱癌的靶向制剂现已进入癌症治疗领域,这是对晚期膀胱癌基因背景更深入了解的直接结果。目前上述相关的靶向制剂包括针对成纤维细胞生长因子和血管内皮生长因子受体的治疗靶标,抗血管药物(贝伐单抗),酪氨酸激酶抑制剂,以及针对免疫检查点调控通路中蛋白的免疫抑制剂等。这些靶向药物制剂单独或者联合传统化疗后,提高了疗效,较传统治疗具有明显优势。The outcomes for patients with advanced bladder cancer remainpoor. The targeted agents have now entered the cancer treatment arena, which is a direct result of a greater understanding of the genetic background of advanced bladder cancer. The new targeted agents include therapies targeting receptors for fibroblast growth factor and endothelial growth factor; anti-angiogenesis agents （bevacizumab）, tyrosine kinase inhibitors, and immune checkpoint inhibitors that target proteins in the immune checkpoint-regulation pathway, which have increased the effect and have obvious advantages over the traditional treatment through either alone application or combination with traditional chemotherapy for advanced bladder cancer.

关 键 词：膀胱癌 靶向治疗 新药物制剂 

分 类 号：R737.14[医药卫生—肿瘤]